The use of Regorafenib, a blocker of multiple protein kinases, including CSF1R, in combination with Nivolumab is currently involved in a trial for improving outcomes for HCC patients based on the synergistic effects of the drugs (NCT04170556). This evidence concerns the gene CSF1R and hepatocellular carcinoma.